Inflammatory Bowel Diseases: Current Medical and Surgical Therapy

Invited Articles
Interdisciplinary Discussion

Further Sections

Review Article
PharmaForum / PharmaNews / PharmaTicker
Meetings and Conferences
### Editorial

**Focus: Inflammatory Bowel Diseases: Current Medical and Surgical Therapy**

Editors: Klar, E. (Rostock); Neurath, M.F. (Erlangen)

**Review Articles**

226 **Inflammatory Bowel Diseases: Current Medical and Surgical Therapy**

Neurath, M.F. (Erlangen); Klar, E. (Rostock)

227 **New Imaging Techniques in the Diagnosis of Inflammatory Bowel Diseases**

Li, Y.; Hauenstein, K. (Rostock)

236 **Medical Therapy of Active Ulcerative Colitis**

Bürger, M.; Schmidt, C. (Jena); Teich, N. (Leipzig); Stallmach, A. (Jena)

246 **Surgical Principles in the Treatment of Ulcerative Colitis**

Kühn, F.; Klar, E. (Rostock)

252 **Occult and Manifest Colorectal Carcinoma in Ulcerative Colitis: How Does It Influence Surgical Decision Making?**

Hardt, J.; Kienle, P. (Mannheim)

259 **Medical Therapy of Fibrostenotic Crohn’s Disease**

Siegmund, B. (Berlin)

265 **Medical Therapy of Perianal Crohn’s Disease**

Klag, T.; Goetz, M. (Tübingen); Stange, E.F. (Stuttgart); Wehkamp, J. (Tübingen)

273 **Indications and Specific Surgical Techniques in Crohn’s Disease**

Seifarsh, C.; Kreis, M.E.; Gröne, J. (Berlin)

280 **Endoscopic Therapy in Inflammatory Bowel Diseases**

Neumann, H.; Neurath, M.F.; Atreya, R. (Erlangen)

**Interdisciplinary Discussion**

287 **Inflammatory Bowel Diseases: Current Medical and Surgical Therapy**

Lamprecht, G. (Rostock) (Chair)
Vol. 31, Issue 4, August 2015

Review Article

290 The New Era of Interferon-Free Treatment of Chronic Hepatitis C
Solbach, P.; Wedemeyer, H. (Hanover)

297 PharmaForum
299 PharmaNews / PharmaTicker
304 Meetings and Conferences
308 Guidelines for Authors
250 Imprint
Guidelines for Authors

Viszeralmedizin
Gastrointestinal Medicine and Surgery

Submission

‘Viszeralmedizin’ is a peer-reviewed journal intended to provide a forum for interdisciplinary discussion of relevant and current questions of visceral surgery, gastroenterology and hepatology.

Please send your manuscript to the Editorial Office:

S Karger Verlag für Medizin und Naturwissenschaften GmbH
Attn: Alexander Eitner
PO Box
79095 Freiburg (Germany)
Tel +49 761 45 20 730
Fax +49 761 45 20 714
a.eitner@karger.com

Language

All contributions must be written in English (American or British spelling and grammar).

Types of Papers and Allotted Number of Pages

Please print the manuscript 1/2-spaced with 3-cm margins (left and right). Use only one format (normal) for the document.

The text should be limited to the following number of pages:

<table>
<thead>
<tr>
<th>Printed pages</th>
<th>Equals approx. characters*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review Article, Original Article</td>
<td>5</td>
</tr>
<tr>
<td>Interdisciplinary Discussion</td>
<td>5</td>
</tr>
<tr>
<td>Case Report</td>
<td>3</td>
</tr>
<tr>
<td>Letter to the Editor</td>
<td>2</td>
</tr>
<tr>
<td>Others</td>
<td>2</td>
</tr>
</tbody>
</table>

* including title page, English summary, illustrations, tables, and references. Each table or figure counts for 1,500 characters.

Each additional complete or partial page to print will be charged to the author.

Conditions

Acceptance of a manuscript is based on the evaluation by several reviewers (peer review). Manuscripts are received with the explicit understanding that the article has not been published, neither wholly nor in part, has not been submitted for publication anywhere else and is not under consideration by any other journal. Submission of an article for publication implies that the authors are the owners of the copyright and that the article does not infringe any existing third party rights, including copyright and intellectual property rights.

It is the authors’ responsibility to obtain permission to produce illustrations, tables, etc. from other publications.

Once the manuscript is accepted for publication, the authors grant S. Karger Publishers a license to publish and reproduce the article in either its present form or revised version for any possible use and identify themselves as the original publishers. This right extends also to associated companies. The publishing rights are worldwide rights and are not time-limited. They include the right to publish the text in printed format as well as electronic online and offline media or databases of any kind. Accepted papers, in whole or in part, may not be translated into other languages, or reproduced by any mechanical or electronic means (including photocopying, recording and microcopying), or stored in a retrieval system without the written consent of the publisher.

All forms of support, including that from drug companies, and any potential source of conflict of interest should be acknowledged in the cover letter to the editor. Should the manuscript be accepted, the editor will discuss the extent of disclosure appropriate for publication with the authors.

The publisher reserves the right to edit the manuscript and decide on the layout.

Conflicts of Interest

Authors are required to disclose any sponsorship or funding arrangements relating to their research, and all authors must disclose any possible conflicts of interest. Disclosure statements will be published at the end of the text of the article.

Ethical and Legal Prerequisites

Manuscripts involving examinations of human subjects must include a statement that the trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendment of 1983, 1989, and 1996 [JAMA 1997;277:925-926]. Accordingly, the subject’s informed consent has to be mentioned in the manuscript. Information suitable to reveal the subject’s identity is to be avoided.

Experiments involving animals demand consent as well and must meet the requirements of German laws for the protection of animals in their current version. A reference to this approval must be included in the manuscript. Articles from countries other than Germany must include a comparable note.

Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Arrangement

Authors’ affiliations and address of correspondence: Each author’s full name, followed by their affiliation (hospital, institute etc. where the work was conducted) and the exact postal address of the corresponding author complete with postal code must be given in a separate document to ensure a blind review process. Please also supply phone and fax numbers, as well as e-mail address.

Title page: The first page of each paper should indicate the title and a short title for use as running head.

Keywords: For indexing purposes, a list of 3-5 keywords is essential. Whenever possible, use keywords such as found in the Medical Subject Headings List (MeSH) of Index Medicus (see www.nlm.nih.gov).

Summary: Summaries must not exceed 200 words each. Summaries of Original Articles and Review Articles should be structured as follows: Background (or Introduction), Patients and Methods (or Material and Methods), Results, Conclusion.

Footnotes: Footnotes should be used only for tables.

Registered Trade Names: When first mentioned, registered trade names must be marked with the superscript registration symbol "TM" or "®". It is the sole responsibility of the author to ensure that this rule is followed properly.

Tables and Illustrations: Tables are part of the text and should be placed at the end of the text file. Illustration data must be stored as separate files. The number of figures and tables should be limited and aim to illustrate the text. Figures are listed in the text as (fig. 1), tables as (table 1). Data already mentioned in the text need not be repeated in a table. Accordingly, numbers used in tables need not be repeated in the text.

Illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 600–800 dpi.

References

The list of references should include only the publications cited in the text.

References must be numbered sequentially in the order cited in the text. In the text identify references by Arabic numerals [in square brackets]. In each reference all authors should be named; the abbreviation ‘et al.’ is to be avoided.

It is recommended to quote only articles already published or accepted for publication. Please avoid ‘in preparation’ or ‘personal communication’.

Authors are responsible for the accuracy and completeness of their references and for correct citation. Journal titles should be abbreviated according to the Index Medicus system (www.nlm.nih.gov). If a reference manager is used, the style “Pharmacology” or “Nephron” should be chosen.

Examples for references can be found at www.karger.com/vim:

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author.

Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.